Trials / Completed
CompletedNCT02013180
Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 480 (actual)
- Sponsor
- Bagcilar Training and Research Hospital · Other Government
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Although Prostate Specific Antigen (PSA) is a useful marker for early detection of the prostate cancer, its specivity is not sufficient. Several PSA variations were defined in order to increase the specivity of the test, but they aren't much more effective than the PSA alone for detection of disease. In older studies reported that, serum and prostatic tissue zinc levels decreased in prostat cancer disease. In our study we aimed to establish the utility of serum zinc, PSA, free PSA/PSA (fPSA/tPSA), zinc/PSA, levels for early detection of the prostate cancer.
Conditions
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2013-01-01
- Completion
- 2017-01-01
- First posted
- 2013-12-17
- Last updated
- 2019-04-16
- Results posted
- 2019-04-16
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT02013180. Inclusion in this directory is not an endorsement.